查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1146375

呼吸困難治療市場——增長、趨勢、COVID-19 的影響和預測 (2022-2027)

Dyspnea Treatment Market - Growth, Trends, and Forecasts (2022 - 2027)
出版日期: | 出版商: Mordor Intelligence | 英文 130 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

在預測期內，呼吸窘迫治療市場預計將以 4.5% 的複合年增長率增長。

根據 2020 年 11 月發表的一項題為“呼吸困難：COVID-19 肺炎的警告症狀消失”的研究結果，呼吸困難發展為急性 SARS-CoV-2 感染，並且是最嚴重的，在隨訪患者中更為常見臨床結果。在一般人群中，呼吸困難與慢性阻塞性肺病患者的不良預後密切相關。同一消息來源還報告說，只有不到 50% 的 SARS-COV-2 感染者出現呼吸困難（主觀呼吸不適）。因此，預計對呼吸困難藥物的需求會增加，但供應鏈薄弱使市場在大流行期間痛苦不堪。

慢性阻塞性肺病和哮喘的患病率不斷上升，這是呼吸困難及其潛在症狀的主要原因，正在推動全球呼吸困難治療市場的發展。呼吸困難的主要原因是心肺疾病的高患病率、人口肥胖的增加和生活方式的改變。 2022 年 2 月發表在《歐洲呼吸雜誌》上的一項題為“人口中老年男性呼吸困難不同維度的患病率和嚴重程度”的研究發現，呼吸急促是心肺疾病的常見症狀，在普通人群中普遍存在。是一種症狀，可以是呼吸急促影響 10-25% 的中年成年人在正常活動期間。因此，預計呼吸困難患病率的增加將導致對其管理和治療的需求增加，從而推動市場擴張。此外，慢性阻塞性肺病和哮喘是呼吸窘迫的主要原因，這些疾病患病率上升將在預測期內推動市場擴張。根據世界衛生組織 (WHO) 2021 年情況說明書，哮喘是一種主要的非傳染性疾病 (NCD)，影響兒童和成人。到 2020 年，全球將有大約 2.62 億人患有哮喘，預計哮喘患者對呼吸困難治療的需求將會增加。

此外，隨著空氣污染水平上升和接觸有毒物質使人們呼吸困難，呼吸困難治療的全球市場正在擴大。根據美國環境保護署 2022 年 6 月的報告，空氣中的臭氧會對健康產生不利影響，臭氧水平可能高到危險的程度，尤其是在炎熱的晴天。。患有哮喘病的人、兒童、老人和從事戶外活動的人都有呼吸含臭氧空氣的風險。因此，增加接觸有毒物質和空氣污染可能會顯著增加發生呼吸窘迫的可能性，從而在預測期內推動市場增長。

因此，雖然上述所有因素都有望在預測期內促進市場增長，但與治療相關的高成本可能會抑制市場增長。

主要市場趨勢

輔助氧療有望在預測期內健康增長

補充氧氣療法使用氧氣作為藥物治療。急性適應症包括低氧血症、一氧化碳中毒和叢集性頭痛。它也可以預防性給藥，以在麻醉誘導期間維持血氧水平。

在患有慢性阻塞性肺病 (COPD) 的低氧血症患者中，氧療通常用於其他慢性肺部疾病（例如呼吸困難）患者，以改善生活質量並提高生存率。將裡克·卡特 (Rick Carter) 於 2022 年 3 月發表的一項題為“長期補充氧療”的研究估計，美國每年有 150 萬患者接受氧療。因此，由於使用氧療治療呼吸困難等呼吸系統疾病的趨勢不斷增加，預計該市場在預測期內將會增長。

2021 年 7 月在《新英格蘭醫學雜誌》上發表的一項題為“補充氧氣的□□管理”的研究報告稱，補充氧氣是治療呼吸困難的最有效因素。補充氧氣療法可改善睡眠、情緒、頭腦清晰度、耐力，並提高患有某些肺部疾病的人執行正常日常任務的能力。氧療有助於預防嚴重肺部疾病患者的心力衰竭。由於氧療的這些好處，市場有望在整個預測期內擴大。

氧療支持資金的擴大預計將加速該行業的發展。例如，2022 年 6 月，美國國際開發署 (USAID) 將推進此前宣布的 5000 萬美元投資計劃，以改善全球醫用氧氣的獲取，從全球 50 個設施開始，致力於建設和加強醫療基礎設施以支持散裝液態氧。美國國際開發署估計，這項投資將有助於為超過 20,000 張病床提供醫用氧氣，使每年有數千名患者能夠接受氧氣治療。此外，全球基金已投資約 6 億美元，幫助 80 多個中低收入國家擴大患者獲得醫用氧氣的機會，美國是該基金最大的單一捐助國。政府的此類努力將減輕患者的負擔，從而加速該行業的發展。

鑑於這些因素，預計該細分市場在預測期內將呈現健康的增長率。

預計在預測期內北美將佔據重要的市場份額

由於主要市場參與者的存在、產品批准的增加、醫療保健系統的不斷發展以及肥胖和心肺疾病的高發率，北美在全球呼吸困難治療市場佔據主導地位。

根據一項名為“美國成年人的呼吸系統症狀”的研究。根據 2022 年 7 月發表在 Pulmonary Therapy 雜誌上的“一項橫斷面健康調查研究”，最常見的呼吸道症狀是排痰性咳嗽和呼吸急促，其次是每年 17% 的美國成年人。據說他是已感染。雖然哮喘、慢性阻塞性肺病 (COPD) 和冠狀動脈疾病是運動時呼吸困難的常見原因，但病態肥胖是報告這種情況的受試者中最常見的合併症。此外，預計這些疾病的患病率增加將推動市場增長。根據 ODPHP（疾病預防和健康促進辦公室）2020，美國有超過 2500 萬人患有哮喘，約有 1480 萬成年人被診斷患有 COPD。

此外，預計大氣人口的增加和有害物質的增加將支持市場擴張。根據美國環境保護署 2022 年 6 月發布的一份報告，美國在 2021 年向大氣排放了約 6700 萬噸污染物。這些排放物是造成臭氧和顆粒物形成、酸沉積和能見度降低的主要原因。這可能會導致一些呼吸系統症狀，例如呼吸困難。

預計臨床試驗的增加將為該疾病引入更好的治療方案，並有望刺激市場擴張。根據 2022 年 2 月 Clinitrials.gov 更新，國家癌症研究所 (NCI) 的一項題為“地塞米松控制癌症患者呼吸困難”的研究發現地塞米鬆在控制癌症患者呼吸困難方面的療效。地塞米鬆有望改善癌症患者的肺功能、減少呼吸困難並改善生活質量 (QOL)。因此，預計它會很快發布並有助於擴大市場。

這樣，由於上述因素，市場有望實現高增長。

競爭格局

由於少數主要市場參與者的存在，該市場是一個綜合市場。隨著技術和產品創新的進步，中小企業通過以具有競爭力的價格向市場推出新設備來增加他們在市場上的存在。市場進入者包括 Mayne Pharma Group Limited、Teva Pharmaceutical Industries Ltd、GlaxoSmithKline 和 Hikma Pharmaceuticals plc。

其他好處

  • Excel 格式的市場預測 (ME) 表
  • 三個月的分析師支持

內容

第一章介紹

  • 研究假設和市場定義
  • 調查範圍

第二章研究方法論

第 3 章執行摘要

第四章市場動態

  • 市場概覽
  • 市場驅動因素
    • 呼吸困難和相關疾病的患病率上升
    • 空氣污染和接觸各種有毒物質的增加
  • 市場製約因素
    • 高昂的治療費用
  • 波特的五力分析
    • 新進入者的威脅
    • 買方/消費者議價能力
    • 供應商的議價能力
    • 替代品的威脅
    • 競爭公司之間的敵對關係

第 5 章市場細分（基於價值的市場規模 - 百萬美元）

  • 按治療類型
    • 按治療方法
      • 氧氣替代療法
      • 放鬆療法
    • 按藥物類別
      • 抗焦慮藥
      • 抗菌藥物
      • 抗膽鹼藥
      • 腎上腺皮質類固醇
      • 其他
  • 最終用戶
    • 醫院
    • 家庭護理
    • 專業設施
    • 其他
  • 按地區
    • 北美
      • 美國
      • 加拿大
      • 墨西哥
    • 歐洲
      • 德國
      • 英國
      • 法國
      • 意大利
      • 西班牙
      • 其他歐洲地區
    • 亞太地區
      • 中國
      • 日本
      • 印度
      • 澳大利亞
      • 韓國
      • 其他亞太地區
    • 世界其他地方

第六章競爭格局

  • 公司簡介
    • Mayne Pharma Group Limited
    • Teva Pharmaceutical Industries Ltd.
    • GlaxoSmithKline plc
    • Bausch Health Companies Inc.
    • Hikma Pharmaceuticals plc
    • Lannett Company, Inc.
    • Amneal Pharmaceuticals LLC
    • Viatris Inc.（Mylan N.V.）
    • Lupin Limited
    • Akron Incorporated
    • ANI Pharmaceuticals, Inc.
    • Pfizer, Inc.
    • Sun Pharmaceutical Industries Ltd.

第七章市場機會與未來趨勢

簡介目錄
Product Code: 92009

Dyspnea Treatment Market is expected to grow at a registered CAGR of 4.5% during the forecast period.

According to the study titled "Dyspnea: The vanished warning symptom of COVID-19 pneumonia" published in November 2020, dyspnea is slightly more common in patients who develop acute SARS-CoV-2 infection and have the worst clinical outcomes. In the general population, in people with chronic obstructive pulmonary disease, dyspnea has been strongly linked to a poor prognosis. Moreover, as per the same source, less than 50% of SARS-COV-2 infected patients had been reported to experience dyspnea, a subjective feeling of breathing discomfort. As a result, it was anticipated that demand for dyspnea treatments would increase; however, because of a weak supply chain, the market suffers during a pandemic

The increase in the prevalence of COPD and asthma, which are the main causes of dyspnea and its causative symptoms, is what is driving the global market for dyspnea treatments. The main causes of dyspnea are a high prevalence of cardiopulmonary diseases, a rise in obesity among people, and alterations in lifestyle. According to the study titled "Prevalence and severity of different dimensions of breathlessness among elderly males in the population" published in the European Respiratory Journal in February 2022, breathlessness has been a common symptom of cardiorespiratory disease, as well as a prevalent symptom in the general population. Shortness of breath affects 10-25% of adults in their middle years and older during regular activity. Therefore, increasing dyspnea prevalence is anticipated to result in increased demand for its management and treatment, which will propel market expansion. Additionally, COPD and asthma are the main contributors to dyspnea, and the rising prevalence of these conditions will fuel market expansion over the forecast period. According to the World Health Organization (WHO) 2021 factsheet, asthma is a major non-communicable disease (NCD), that affects both children and adults. Globally, around 262 million people had asthma in 2020, which is expected to boost the demand of dyspnea treatment among people suffering from Asthma.

Furthermore, the global market for dyspnea treatments is expanding as a result of rising air pollution levels and toxicity exposure that causes breathlessness in the populace. According to the United States Environmental Protection Agency in June 2022, health could be negatively impacted by ozone in the air, especially on hot, sunny days when ozone levels could rise dangerously high. People with asthma, children, elderly people, and those who engage in outdoor activities were at risk from breathing ozone-containing air. Thus, increasing exposure to toxic substances and air pollution may significantly increase the likelihood of developing dyspnea, fueling the market growth over the projected period.

Thus, all aforementioned factors are expected to boost the market growth over the forecast period, however, the high cost associated with the treatment may restrain the market growth.

Key Market Trends

Supplemental Oxygen Therapy is Expected to Witness Healthy Growth Over the Forecast Period

Supplemental oxygen is the use of oxygen as a medicinal treatment. Acute indications for therapy include hypoxemia, carbon monoxide poisoning, and cluster headache. It may also be administered prophylactically to maintain blood oxygen levels during anesthesia induction.

Patients with other chronic lung diseases such as dyspnea are frequently prescribed oxygen therapy because it improves the quality of life and increases survival in hypoxemic patients with chronic obstructive pulmonary disease (COPD). According to the study titled "Long-term supplemental oxygen therapy" by Rick Carter published in March 2022, in the United States, 1.5 million patients received oxygen therapy each year. Thus, it is anticipated that the market will grow during the forecast period due to the rising trend of using oxygen therapy for respiratory conditions, including dyspnea.

According to the study titled "Administration of Supplemental Oxygen" published in the New England Journal of Medicine in July 2021, the study reported that supplemental oxygen is the most effective component in the treatment of dyspnea. Supplemental oxygen therapy improves sleep, mood, mental clarity, endurance, and the ability of people with some types of lung disease to perform regular, everyday tasks. In patients with severe lung diseases, additional oxygen therapy helps prevent heart failure. As a result of the additional advantages of oxygen therapy, the market is anticipated to expand throughout the forecast period.

Growing funding for oxygen therapy support is anticipated to accelerate the segment's growth. For instance, in June 2022, the United States Agency for International Development (USAID) has advanced plans for a previously announced USD 50 million investment to increase access to medical oxygen worldwide, beginning with commitments to build and enhance health care infrastructure to support bulk liquid oxygen in 50 facilities around the world. According to estimates from USAID, the investment will support the provision of medical oxygen at more than 20,000 beds, allowing thousands of patients to receive oxygen therapy every year. Moreover, the Global Fund invested around USD 600 million to help more than 80 lower-middle-income countries increase patient access to medical oxygen, and the United States is the fund's single-largest donor. Such government initiatives lower the cost for the patient population, which ultimately accelerates the segment's growth.

Thus, owing to the above factors the segment is expected to show a healthy growth rate over the forecast period.

North America is Expected to Hold a Significant Market Share Over the Forecast Period

North America dominated the global dyspnea treatment market due to the presence of major market players, an increase in product approvals, a developed health care system, and a high prevalence of obesity and cardiopulmonary diseases.

According to the study titled "Respiratory Symptoms among US Adults: A Cross-Sectional Health Survey Study" published in Pulmonary Therapy in July 2022, the most common respiratory symptom, followed by a productive cough and shortness of breath, affects 17% of adult Americans every year. Morbid obesity was the most common comorbidity in subjects reporting this symptom, even though asthma, chronic obstructive pulmonary disease (COPD), and coronary heart disease were common causes of dyspnea on exertion. Moreover, the growing prevalence of these diseases is expected to boost the market growth. As per the Office of Disease Prevention and Health Promotion (ODPHP) 2020, more than 25 million people in the United States had asthma and approximately 14.8 million adults have been diagnosed with COPD.

Additionally, it is anticipated that a growing air population and harmful toxins will support market expansion. The United States Environmental Protection Agency in June 2022, in the United States, approximately 67 million tons of pollution were released into the atmosphere in 2021. These emissions primarily cause ozone and particle formation, acid deposition, and reduced visibility. this might result in several respiratory conditions, like breathing difficulties (dyspnea).

A growing number of clinical trials are anticipated to introduce better treatment options for diseases, which is anticipated to spur market expansion. According to the Clinitrials.gov updates in February 2022, the study titled "Dexamethasone in Controlling Dyspnea in Patients with Cancer" by the National Cancer Institute (NCI), the study has accessed the effectiveness of dexamethasone in managing dyspnea in cancer patients. In cancer patients, dexamethasone may enhance lung function, reduce dyspnea (shortness of breath), and enhance the quality of life. So, it may be anticipated that this will launch soon and aid in the expansion of the market under consideration.

Thus, owing to all above-mentioned factors the market is expected to witness high growth

Competitive Landscape

The market studied is a consolidated market owing to the presence of a few major market players. With the rising technological advancements and product innovations, mid-size and small-scale companies are increasing their market presence by introducing new devices into the market at competitive prices. Some of the market players are Mayne Pharma Group Limited, Teva Pharmaceutical Industries Ltd, GlaxoSmithKline, Hikma Pharmaceuticals plc, and others.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising in Prevalence of Dyspnea and its Associated Disorders
    • 4.2.2 Increasing Levels of Air Pollution and Exposure to Various Toxins
  • 4.3 Market Restraints
    • 4.3.1 High Costs Associated with The Treatment
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD Million)

  • 5.1 By Treatment type
    • 5.1.1 By Therapy
      • 5.1.1.1 Supplemental Oxygen Therapy
      • 5.1.1.2 Relaxation Therapy
    • 5.1.2 By Drug Class
      • 5.1.2.1 Antianxiety Drugs
      • 5.1.2.2 Antibiotics
      • 5.1.2.3 Anticholinergic Agents
      • 5.1.2.4 Corticosteroids
      • 5.1.2.5 Others
  • 5.2 By End User
    • 5.2.1 Hospitals
    • 5.2.2 Home Care
    • 5.2.3 Specialty Centers
    • 5.2.4 Others
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Rest of the World

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Mayne Pharma Group Limited
    • 6.1.2 Teva Pharmaceutical Industries Ltd.
    • 6.1.3 GlaxoSmithKline plc
    • 6.1.4 Bausch Health Companies Inc.
    • 6.1.5 Hikma Pharmaceuticals plc
    • 6.1.6 Lannett Company, Inc.
    • 6.1.7 Amneal Pharmaceuticals LLC
    • 6.1.8 Viatris Inc. (Mylan N.V.)
    • 6.1.9 Lupin Limited
    • 6.1.10 Akron Incorporated
    • 6.1.11 ANI Pharmaceuticals, Inc.
    • 6.1.12 Pfizer, Inc.
    • 6.1.13 Sun Pharmaceutical Industries Ltd.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS